MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 07.03.2026
Aptorum Group Limited Operativer Cashflow 2011-2026 | APM
Operativer Cashflow Jährlich Aptorum Group Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.19 M | -7.72 M | -12.3 M | -14.7 M | -15.9 M | -13.4 M | -10 M | -5.78 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -1.19 M | -15.9 M | -10.1 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
BridgeBio Pharma
BBIO
|
-446 M | $ 65.64 | 0.43 % | $ 12.6 B |  USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.52 | 2.03 % | $ 1.05 B |  Canada |
 |
Biogen
BIIB
|
2.2 B | $ 188.24 | 1.82 % | $ 27.6 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
BeyondSpring
BYSI
|
-16.4 M | $ 1.48 | 2.07 % | $ 59.7 M | USA |
 |
Cabaletta Bio
CABA
|
-53.5 M | $ 3.27 | 3.15 % | $ 3.82 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 12.02 | -0.41 % | $ 791 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Annovis Bio
ANVS
|
-40 M | $ 2.57 | 3.21 % | $ 23.2 M | USA |
 |
Coherus BioSciences
CHRS
|
-175 M | $ 1.93 | 6.04 % | $ 182 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.6 | 1.12 % | $ 116 M | France |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-233 M | $ 4.23 | 2.92 % | $ 105 M |  Schweiz |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Collegium Pharmaceutical
COLL
|
329 M | $ 37.27 | -0.05 % | $ 1.18 B | USA |
 |
Cellectar Biosciences
CLRB
|
-23.1 M | $ 2.75 | -0.36 % | $ 7.17 M | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
142 M | $ 33.99 | 0.35 % | $ 3.53 B | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 24.79 | 2.27 % | $ 3.03 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-36.1 M | $ 9.55 | 19.23 % | $ 41.3 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Cardiff Oncology
CRDF
|
-37.9 M | $ 1.99 | 5.85 % | $ 133 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
CorMedix
CRMD
|
175 M | $ 6.56 | 1.55 % | $ 473 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-378 M | $ 38.22 | -0.03 % | $ 3.59 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 58.78 | 4.04 % | $ 5.29 B | Schweiz |
 |
Champions Oncology
CSBR
|
7.39 M | $ 5.97 | 1.7 % | $ 81.5 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.59 | 4.66 % | $ 8.64 B |  Australia |
 |
Cue Biopharma
CUE
|
-36.3 M | $ 0.3 | 0.4 % | $ 16.9 M | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Atara Biotherapeutics
ATRA
|
-68.7 M | $ 6.68 | 29.21 % | $ 50 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-17.1 M | $ 3.05 | 3.74 % | $ 1.17 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-33.1 M | $ 1.2 | - | $ 36.1 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-510 M | $ 62.42 | 3.33 % | $ 7.5 M | USA |